Half-year report · Q2
3750.TEDINET S100US7P
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥91m | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥1.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥863m | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | −¥407m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | −¥354m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥420m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥907m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥424m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥432m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥419m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥432m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥138m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥443m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥433m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | −¥443m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥5.1bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥5.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥13.6bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.8bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.3bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥2.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.2bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥522m | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥522m | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥208m | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥673m | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥421m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥367m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥8.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥102m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥94m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-48.42 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.47 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-49.65 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥15.42 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 41.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 14.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥144m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥65m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥65m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥206m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥27m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥27m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥57m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥91m |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥91m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | −¥263m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥87m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥45m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥45m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥285m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥818m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥818m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥17m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥863m |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥863m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | −¥267m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 444
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1YTDDuration | 862531000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05443-000MedicalAssetManagemetReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05443-000RealAssetManagementReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05443-000MedicalAssetManagemetReportableSegmentsMember | 44646000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05443-000RealAssetManagementReportableSegmentsMember | 817885000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 862531000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Net sales | Prior1YTDDuration | 862531000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05443-000MedicalAssetManagemetReportableSegmentsMember | -284847000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05443-000RealAssetManagementReportableSegmentsMember | 17430000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | -267417000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -86654000 | JPY |
| Operating income | Prior1YTDDuration | -354071000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05443-000MedicalAssetManagemetReportableSegmentsMember | 64868000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05443-000RealAssetManagementReportableSegmentsMember | 26565000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 91433000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 91433000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05443-000MedicalAssetManagemetReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05443-000RealAssetManagementReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05443-000MedicalAssetManagemetReportableSegmentsMember | 64868000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05443-000RealAssetManagementReportableSegmentsMember | 26565000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 91433000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Net sales | CurrentYTDDuration | 91433000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05443-000MedicalAssetManagemetReportableSegmentsMember | -206192000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05443-000RealAssetManagementReportableSegmentsMember | -56707000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | -262900000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -144395000 | JPY |
| Operating income | CurrentYTDDuration | -407295000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第21期中（自 2024年４月１日 至 2024年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社サイトリ細胞研究所 | |
| Company name in english cover page | FilingDateInstant | Cytori Cell Research Institute,Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役会長兼社長 星野 喜宏 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区大手町一丁目１番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03－6860－5701 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経営企画部長 藤村 剛 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区大手町一丁目１番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03－6860－5701 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営企画部長 藤村 剛 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |